Kymera Therapeutics Sets Up Year-End Catalyst With KT-621 Data on Deck
Kymera’s third-quarter update pairs positive KT-579 Phase 1 results with a year-end 2026 KT-621 Phase 2b readout.
Iovance Stock Jumps as Lifileucel Combination Delivers 62.5% Response Rate
Iovance’s frontline melanoma data could broaden lifileucel’s opportunity, but the result is not yet a commercial or regulatory conclusion.
Cullinan Therapeutics’ FDA IND Clearance Moves Velinotamig Toward Global Autoimmune Trials
Cullinan Therapeutics’ FDA IND clearance moves velinotamig into global clinical development for autoimmune cytopenias, a key pipeline transi…
Genmab ADR Surges 16.8% as Biotech Traders Revisit Catalyst and M&A Speculation
Genmab’s GMAB ADR surged 16.8% in morning trading, putting M&A speculation, catalysts and biotech peer sentiment back in focus.
Eli Lilly’s Retatrutide Data Raises Stakes in the GLP-1 Drug Race
New retatrutide trial data may strengthen Eli Lilly’s position in the GLP-1 market, while raising expectations for its next-generation pipel…
Moderna’s $181.36 Support Level Faces Test After Mixed Melanoma Data
Moderna is holding reported $181.36 support after mixed melanoma vaccine data narrowed the benefit seen in Phase 2b.
Merck’s Phase III Oncology Results Put Its 2027 Pipeline Under the Microscope
Merck’s TroFuse-005 update puts its oncology pipeline at the center of the post-Keytruda growth debate heading into 2027.
Incyte’s $152 Price Target Holds as H.C. Wainwright Reviews Cancer-Drug Data
H.C. Wainwright kept Incyte’s $152 price target after reviewing new cancer-drug data, signaling continued attention without a rating change.
Summit Therapeutics’ $30 Target Holds as Ivonescimab Data Deliver Another Phase 3 Win
Back-to-back bullish analyst calls follow additional ivonescimab data, keeping Summit Therapeutics and its clinical catalyst profile in focu…
Pfizer’s Talzenna-Xtandi Approval Expansion Adds New Oncology Catalyst for PFE
The FDA’s expanded approval of Pfizer’s Talzenna-Xtandi combination gives PFE a fresh regulatory catalyst in metastatic prostate cancer.
SciSparc Stock Jumps 38.56% as Traders Track SCI-110 and AI Pivot
SciSparc shares rose 38.56% as traders focused on the SCI-110 trial and an AI pivot, though confirmed clinical and commercial details remain…
Aurora Cannabis Investors Weigh Alberta Securities Commission Decision
The Alberta Securities Commission dismissed a Curaleaf application, giving Aurora investors a regulatory signal—but no reported earnings or …











